Type-1 hepatorenal syndrome in patients with cirrhosis and infection vs. sepsis-induced acute kidney injury: What matters?  by Francoz, Claire & Durand, François
EditorialType-1 hepatorenal syndrome in patients with cirrhosis and infection
vs. sepsis-induced acute kidney injury: What matters?
Claire Francoz, François Durand⇑
Hepatology & Liver Intensive Care, INSERM U773, Centre de Recherche Biomédicale Bichat Beaujon CRB3, Hospital Beaujon, Clichy, FranceSee Article, pages 955–961Type-1 hepatorenal syndrome (HRS) is considered to be a speciﬁc
complication of advanced cirrhosis characterized by an abrupt
pre-renal like deterioration in renal function, unresponsive to
volume expansion and associated with an especially poor prog-
nosis [1]. With the aim of better reﬂecting the speciﬁcity of
HRS, the original deﬁnition was very stringent with a number
of exclusion criteria such as ongoing sepsis [2]. With increasing
experience, it was felt that these diagnostic criteria were too
restrictive since HRS is frequently triggered by precipitating fac-
tors. Accordingly, since revised guidelines have been proposed in
2007, bacterial infection is no longer considered to be an exclu-
sion criterion for the diagnosis of HRS [3].
The main mechanism of HRS is an extreme renal vasoconstric-
tion due to the activation of sodium-retaining and vasoconstric-
tor systems resulting in a major decrease in glomerular
ﬁltration rate (GFR) [4]. This cascade of events results from
marked splanchnic vasodilatation and a state of low effective
arterial blood volume. Insufﬁcient cardiac output may also con-
tribute to renal hypoperfusion. A paradox is that the reference
treatment of HRS, where renal vasoconstriction is central, is
based on a potent vasoconstrictor agent: terlipressin. Practically,
this apparent paradox could be explained by the fact that terli-
pressin-induced vasoconstriction predominates in the splanchnic
system. Terlipressin may reverse, at least in part, splanchnic arte-
rial vasodilatation with redistribution to systemic vascular bed
and reversal of reduced effective arterial blood volume. While
only few data are available on type-2 HRS, several studies have
shown that terlipressin improves renal function in up to 65% of
patients with type-1 HRS with a signiﬁcant improvement in sur-
vival [5–8]. Unfortunately, in the absence of transplantation,
short term mortality remains very high. However, in all these
studies patients with ongoing sepsis were excluded according
to the original deﬁnition of HRS. In this issue of the Journal of
Hepatology [9], Rodriguez E. and colleagues report on the resultsJournal of Hepatology 20
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Open access under CC BY-NC-ND license.of a pilot study exploring the role of terlipressin and albumin in
patients with type-1 HRS and sepsis. Interestingly, the authors
found that in this subgroup, results similar to those previously
reported in patients without sepsis could be achieved. Response
to therapy (decrease in serum creatinine below 1.5 mg/dl or
133 lmol/L) was observed in 67% of patients. The response rate
was higher as compared to a historical group of patients with
type-1 HRS not treated by terlipressin and albumin even if the
difference did not reach signiﬁcance (67% vs. 40%, p = 0.06).
Three-month survival rate was signiﬁcantly higher in responders
as compared to non-responders. These results strongly support
the use of terlipressin and albumin in patients with type-1 HRS
and bacterial infection. However, they should be interpreted with
caution since the study population was relatively small and there
was no control group. Even though controlled studies are unlikely
to be performed in this uncommon condition, the results might
be validated in other centers.
The results of this study also support the concept that, what-
ever patients with cirrhosis have bacterial infection or not, the
mechanisms of type-1 HRS are similar. Indeed, in this population
of patients with infection, response to terlipressin was character-
ized by an improvement of circulatory function along with a sig-
niﬁcant decrease in plasma renin activity and plasma
norepinephrine concentration. However, these results should be
interpreted in the light of the recently revisited mechanisms of
sepsis-induced acute kidney injury (AKI) in non-cirrhotic
patients, suggesting that many factors other than renal hypoper-
fusion are involved. An increasing body of evidence shows that
sepsis-induced AKI is a complex process where several factors
including microcirculatory changes, patchy areas of tubular cells
with apical vacuolization but no necrosis or apoptosis and,
ﬁnally, metabolic downregulation of tubular cells induced by
inﬂammation and oxidative stress come into play [10]. Besides
microcirculatory changes and extraglomerular shunting, these
tubular changes may lead to decreased GFR through activation
of the tubuloglomerular feedback, constriction of the afferent
arteriole and decreased hydrostatic pressure in the glomerulus.
These mechanisms may explain why sepsis-induced AKI can be
observed in the absence of overt renal hypoperfusion [11].
Whether similar mechanisms are involved in type-1 HRS associ-
ated with infection is an important issue, especially in those who
do not respond to terlipressin. The absence of signiﬁcant increase14 vol. 60 j 907–909
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in urinary neutrophil gelatinase associated lipocalin (a biomarker
of acute tubular necrosis) in non-responders as compared to
responders is consistent with the changes observed during sep-
sis-induced AKI, as described above. However, the respective role
of renal vasoconstriction and hypoperfusion on the one hand and
the mechanisms involved in sepsis-induced AKI other than hypo-
perfusion on the other hand needs to be further investigated. In
general efforts should be made in the development of tools to
monitor renal blood ﬂow. Such tools may obviously help opti-
mize the management.
According to the deﬁnition proposed recently by the
EASL-CLIF Consortium [12], all patients in the study by Rodri-
guez E. and colleagues [9] met the criteria for acute-on-chronic
liver failure (ACLF). Indeed, all patients had cirrhosis and serum
creatinine above 2 mg/dl (180 lmol/L). ACLF and the derived
CLIF-SOFA score [12] allow to categorize patients with cirrhosis
and acute deterioration according to the number and severity of
organ/system failures. The CLIF-SOFA score is a prognostic score
derived from the widely used SOFA score in general intensive
care unit patients [13], with some modiﬁcations aimed at better
reﬂecting the impact of organ/system failures in the context of
cirrhosis. The higher the CLIF-SOFA score, the higher the mortal-
ity rate in patients with ACLF. The study by Rodriguez E. and
colleagues offers an original approach allowing to analyze the
impact of type-1 HRS not only as a single event during the
course of cirrhosis but rather as one of the extra-hepatic compli-
cations that may occur during end stage cirrhosis. It is not sur-
prising that in this study, non-responders had a signiﬁcantly
higher CLIF-SOFA score as compared to responders. Nor is it sur-
prising that the higher the CLIF-SOFA score, the higher the mor-
tality rate. Interestingly, the authors found that patients with
ACLF grade 3 as well as those with a CLIF-SOFA score over 11
had a very low probability of response to terlipressin and albu-
min. Since there was a strong interaction between resolution of
infection and severity of ACLF, the absence of resolution of
infection was also associated with a low probability of response
to therapy. Altogether, these ﬁndings illustrate the determining
impact of extra-hepatic organ failures on reversibility of type-1
HRS with terlipressin. Whether in this subgroup of patients,
terlipressin is ineffective because the mechanisms involved are
relatively independent of renal hypoperfusion (such as in
sepsis-induced AKI) or because patients relentlessly progress
to acute tubular necrosis needs to be clariﬁed.
Finally, another factor that should be taken into account is
the presence or absence of underlying chronic kidney changes.
In advanced cirrhosis, indeed, normal baseline serum creatinine
does not exclude a major impairment in renal function [14,15].
In a series of patients with cirrhosis who had transvenous renal
biopsy for increased serum creatinine (>1.5 mg/dl) and no pro-
teinuria, some of whom met the criteria for HRS, none had nor-
mal histology [16]. Chronic kidney changes were found in 77%
of patients. In most patients injuries to different structures were
combined. Signiﬁcant glomerular lesions could be observed in
the absence of proteinuria. Such lesions are likely to be related
to comorbidities. It is conceivable, although not clearly demon-
strated, that patients with end-stage cirrhosis, underlying
chronic kidney changes and a precipitating event such as sepsis
are at higher risk to develop ‘‘acute-on-chronic renal failure’’
[17]. In those meeting the criteria for type-1 HRS, chronic
kidney changes may preclude improvement with terlipressin
and favor the occurrence of extra-hepatic organ failures.908 Journal of Hepatology 201Unfortunately, renal biopsy is impractical in these patients
and biomarkers that clearly differentiate acute (reversible) from
chronic (irreversible) kidney changes are missing.
In summary, the study by Rodriguez E. and colleagues [9]
suggests that the response rate to terlipressin and albumin of
type-1 HRS in patients with cirrhosis is similar whatever sepsis
is present or absent. There is no clear evidence that the
complex mechanisms involved in sepsis-induced AKI have a
signiﬁcant impact on type-1 HRS associated with sepsis since
response to therapy and general course are similar to those
observed in cirrhotic patients without infection. These ﬁndings
suggest that renal macro and microvascular changes induced
by sepsis are different in cirrhotic patients as compared to
non-cirrhotic patients. However, not all patients with type-1
HRS and sepsis respond to terlipressin and albumin. In non-
responders, the prognosis remains especially poor. What
matters in this subgroup seems to be the number and severity
of organ failure(s).Conﬂict of interest
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